Preclinical imaging developer MILabs has secured an installation of its Vector6 PET/SPECT/CT system, with Bayer to assist with oncology research activities.
Bayer will use the system to develop its targeted alpha therapy programs for oncology, MILabs said. The purchase was made as part of Bayer's collaboration with the University of Oslo and the Norwegian Medical Cyclotron Center, according to the firm.
